Highest-materiality recent filing
TriSalus annual meeting elects two directors, ratifies auditor, approves say-on-pay frequency
Mary Szela and Gary Gordon elected to three-year director terms with ~92% for votes.
TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M
Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
TriSalus Life Sciences Chief of Clinical Operations Jodi Devlin to retire October 1, 2026
Jodi Devlin notified Company on April 24, 2026 of retirement as Chief of Clinical Operations.
TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026
Annual base salary of $525,000; sign-on bonus of $250,000.
TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M
Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
TriSalus prices $40M public offering of 9.76M shares at $4.10/share
Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).
TriSalus Life Sciences appoints Michael Stansky to board, replacing Dr. Desai
Dr. Arjun "JJ" Desai resigned from the board on February 3, 2026; no disagreement with the company.
TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M
Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.
Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.
TriSalus director Sean Murphy resigns from Board and Science Committee
Sean Murphy resigned from the Board and the Science and Technology Committee effective September 30, 2025.
TriSalus Life Sciences raises CFO base salary to $550K, grants performance-based stock options
CFO David Patience's annual base salary increased from $450K to $550K, effective immediately.
TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M
Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.
TriSalus completes Preferred Stock exchange; 98.82% tendered at 3.3 common shares each
Approximately 98.82% of outstanding Series A Convertible Preferred Stock (3,551,502 shares) validly tendered in exchange offer.
TriSalus launches exchange offer for Series A Preferred, up to 11.9M common shares
Offers up to 11,860,206 common shares in exchange for each share of Series A Convertible Preferred at $4.00 per share based on liquidation preference plus accrued dividends through Aug 10, 2027.
TriSalus shareholders elect Wahlström and Matlin to board, ratify Grant Thornton
Mats Wahlström and David J. Matlin elected to three-year terms with 20,002,109 and 20,005,151 votes for, respectively; 5,978,753 broker non-votes each.
TriSalus Life Sciences appoints David Patience as CFO; James Young resigns
CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.
TriSalus Q1 rev $9.2M (+42% YoY); revises 2025 guidance: 50% growth, no adj. EBITDA positive
Net sales $9.2M, up 42% YoY and 11% sequential; gross margin 84% vs 85%.
TriSalus announces $22M private placement, Q1 revenue up 42% to $9.2M
Private placement of 5.5M shares at $4.00/share raises ~$22M gross; led by Nantahala Capital, Broadfin Holdings. Expected close May 2, 2025.
TriSalus director George Kelly Martin resigns effective April 20, 2025
Martin resigned from Board, Audit Committee, and Compensation Committee effective immediately.
TriSalus board member Liselotte Hyveled resigns; no disagreement cited
Liselotte Hyveled resigned from the Board, Nominating and Corporate Governance Committee, and Science and Technology Committee, effective April 16, 2025.
TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors
Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.
TriSalus Life Sciences officer Sean Murphy to step down Feb 28, remains on board
Sean Murphy notified intent to step down as officer and employee effective February 28, 2025.
TriSalus draws $10M under senior secured credit facility; issues warrants for 91,263 shares
Closed Second Tranche of $50M credit facility, receiving $10M on Feb 18, 2025.
TriSalus draws $10M from OrbiMed credit facility upon hitting $30M revenue milestone
$10 million drawdown under $50M credit agreement with OrbiMed triggered by achievement of $30M trailing 12-month product revenue milestone as of Jan 31, 2025.
TriSalus Life Sciences appoints two new directors, expands board to 11
William Valle (Class I, term to 2027) and Gary Gordon (Class III, term to 2026) appointed Jan 29, 2025.
TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025
Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.
TriSalus promotes James Young to CFO; appoints new CCO and Chief of Clinical Operations
James Young promoted to CFO, effective Jan 6, 2025; annual base salary $420k, target bonus 50%.
TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025
Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.
TriSalus: Director Anil Singhal resigns; CMO Steven Katz departs
Director Anil Singhal resigned from Board, Compensation and Science/Technology committees effective Oct 28, 2024; no disagreement.
TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed
Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.
TriSalus Life Sciences completes warrant exchange, issues 2.1M shares at 0.3 per warrant
Issued 2,110,366 shares of common stock in exchange for tendered warrants at a ratio of 0.3 shares per warrant.
TriSalus completes warrant exchange; 78.9% of public warrants tendered; warrant amendment enacted
6,533,614 Public Warrants (78.89%) tendered for 0.30 shares each; settlement by July 1, 2024.
TriSalus launches warrant exchange offer at 0.3 shares per warrant; seeks to reduce dilution
Offering up to 4,264,532 common shares for up to 14.2M warrants (0.30 per warrant).
TriSalus Q1 revenue up 116% to $6.5M, secures $50M OrbiMed debt facility
Revenue of $6.5M in Q1 2024, up 116% YoY; gross margin improved to 85% from 78%.
TriSalus Life Sciences appoints Liselotte Hyveled to Board, effective May 6
Board size increased to ten directors; Hyveled appointed as Class I director, term expiring at 2024 annual meeting.
TriSalus Life Sciences secures up to $50M debt financing from OrbiMed; $25M funded at close
$25M funded on April 30, 2024; up to $25M additional available in two tranches subject to revenue thresholds.
TriSalus dismisses KPMG, hires Grant Thornton; KPMG cited going concern
Dismissed KPMG as auditor on April 12, 2024; KPMG's reports included a going concern emphasis citing recurring losses.
TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors
Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.
TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)
Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).
TriSalus Life Sciences grants CFO Sean Murphy option for 125,000 shares at $9.28
Granted on Jan 24, 2024, under the 2023 Equity Incentive Plan.
Company furnished investor presentation (Exhibit 99.1) covering preliminary 2023 full-year sales and business update.
TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months
Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.
Entered Standby Equity Purchase Agreement to sell up to $30M common stock to Yorkville at 96-97% of VWAP.
Slide deck posted on company website for investor use; no earnings, guidance, or corporate updates provided.
TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study
Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.
MedTech Acquisition shareholders approve TriSalus merger; $9.4M redeemed
All 14 proposals approved by >99% of votes cast at August 8 special meeting.
FDA requests additional dose study for TriSalus SD-101; NDA likely beyond 2025
TriSalus received FDA written responses on July 31, 2023 for PERIO-01 Type B meeting regarding SD-101 for metastatic uveal melanoma.
Special meeting for TriSalus business combination adjourned to August 8, 2023 at 11:00 a.m. ET.
MedTech Acquisition regains Nasdaq MVLS compliance threshold
Received Nasdaq notice on June 14, 2023 for non-compliance with $35M MVLS requirement.
MedTech Acquisition raises additional $22.3M in PIPE for TriSalus merger; amends merger agreement
Entered into subscription agreements for 2,229,500 shares of Series A Preferred at $10/share, aggregate $22,295,000.
On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.
As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medical Officer of the Company, effective June 29, 2026.
Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.
On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.
On April 20, 2025, George Kelly Martin informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately.
On April 16, 2025, Liselotte Hyveled informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of her decision to resign from her position as a member of the Board, the Nominating and Corporate Governance Committee of the Board and the Science and Technology Committee of the Board, effective immediately.
On February 19, 2025, Sean Murphy notified TriSalus Life Sciences, Inc. (the “Company”) of his intent to step down as an officer and employee of the Company effective February 28, 2025.
On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.
On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.
promoting James Young to Chief Financial Officer, Secretary, Treasurer and principal financial and accounting officer of the Company
appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer
Effective October 29, 2024, Steven Katz, M.D., the Company’s Chief Medical Officer, is no longer employed by the Company.
Max materiality 0.85 · Median 0.65 · Most common event other_material